People with myasthenia gravis (MG) who are receiving immunosuppressive therapy are more likely to be hospitalized for a COVID-19 infection, yet the majority of patients are discharged without any complications, a single center study reports. “Immunosuppressive therapy was continued during COVID-19 infection,” and “most of hospitalized patients were discharged…
Read more
Two investigational UCB treatments for generalized myasthenia gravis (gMG) — zilucoplan and rozanolixizumab — continue to show benefits in gMG patients, according to recently reported findings from Phase 3 trials. Both delivered as subcutaneous (under-the-skin) injections, zilucoplan works by blocking an immune system protein called C5 that…
The U.S. Food and Drug Administration has granted orphan drug status to NMD670, an experimental oral therapy that NMD Pharma is developing as a potential treatment for myasthenia gravis (MG). The designation is given to therapies intended for treating rare diseases, defined as those affecting fewer than…
Columnist Shawna Barnes offers important information and considerations for anyone wondering, “Should I get a service dog?”
Visit the Myasthenia Gravis News forums to connect with others in the myasthenia gravis community.
Becoming educated and informed about MG is a good first step. Learn general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your MG journey.
There is no cure for MG yet, but there are treatments that can help manage the disease. Learn more about approved and experimental therapeutic approaches here.
Get regular updates to your inbox.
